Chester porphyria

Summary

Chester porphyria (MONDO:0022714) is a disease and 1 clinical trial. Top therapeutic interventions include vecuronium, cisatracurium, and rocuronium. A subtype of inherited porphyria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chester porphyria
Mondo ID	MONDO:0022714
OMIM	176010
UMLS	C0268322
MedGen	82789
Is cancer (heuristic)	no

Also known as: PORC · porphyria, Chester type

Disease family

This is a subtype of inherited porphyria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary skin disorder › hereditary photodermatosis › inherited porphyria › chester porphyria

Related subtypes (8): erythropoietic protoporphyria, cutaneous porphyria, porphyria due to ALA dehydratase deficiency, erythropoietic uroporphyria associated with myeloid malignancy, UROD-related inherited porphyria, HMBS-related hepatic porphyria, PPOX-related hepatic porphyria, CPOX-related hereditary coproporphyria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01690338	PHASE4	UNKNOWN	A Study of Residual Curarization Incidence in China

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VECURONIUM	4	3
CISATRACURIUM	4	1
ROCURONIUM	4	1
CHEMBL4067090	0	1